UKHSA moves PFAS exposure research from concern to measurement
The UK Health Security Agency has started a human biomonitoring study designed to put numbers on an increasingly familiar public health worry: how much PFAS, and related environmental chemicals, are actually present in people living in the UK. The project will use blood and urine samples collected through Health Survey England to measure baseline exposure levels across the population and to strengthen the evidence base for future research.
That shift matters because PFAS concern has often outpaced the clinical data needed to interpret individual results. These are human-made compounds that have been used in industrial processes and consumer products for years, and their persistence in the environment has made them a focus for regulators, researchers, and communities alike. Measuring them in people is not the same as proving harm, but it is the first step toward understanding whether exposure patterns in the UK differ by geography, age, or other background factors.
UKHSA’s programme is not limited to PFAS alone. The same samples will also be analysed for lead, arsenic, bisphenols, phthalates, and flame retardants, creating a broader picture of everyday chemical burden. In practical terms, this type of biomonitoring helps answer a simple but clinically relevant question: what substances are present, and at what levels, in the general population rather than only in highly exposed occupational or environmental clusters?
Baseline exposure data will shape the next phase of risk assessment
The agency has already published an evidence review examining the available research on PFAS and health outcomes, and the biomonitoring study now adds a population-level measurement layer to that literature. Initial findings are expected in 2027. Until then, the study’s value lies in establishing typical background levels, which can serve as a reference point for future surveillance and policy decisions.
PFAS do not behave like a short-lived exposure that disappears quickly from the body. Their persistence is exactly why biomonitoring is useful: detection in blood or urine can show whether the compounds are present, even when the clinical meaning of a particular concentration remains uncertain. That uncertainty is central to the current public health debate. A detectable chemical level does not automatically translate into disease, and biomarker data must be interpreted alongside toxicology, epidemiology, and real-world exposure patterns.
Dr Edward Wynne-Evans, UKHSA’s Director of Radiation, Chemicals, Climate and Environmental Hazards, addressed the evidence gap directly. The strongest signals available so far point to possible associations with raised cholesterol and potentially lower birth weight, but the agency is equally clear that more work is needed to define what those associations mean in long-term health terms. In other words, the biomonitoring project is not trying to answer only whether PFAS can be measured; it is trying to clarify how measurement may eventually translate into risk stratification.
One sentence in the update captures the clinical dilemma neatly: there is no established intervention linked to a specific PFAS blood level.
Why routine PFAS blood testing is not recommended
UKHSA is not currently recommending routine blood testing for PFAS, and the reasoning is grounded in clinical utility rather than denial of exposure concerns. A test is only useful when the result leads to a clear action. At present, a positive PFAS result can confirm presence, but it cannot direct a validated treatment, surveillance pathway, or exposure threshold that reliably changes patient management.
That is the key reason routine testing remains outside normal practice. Without a proven intervention tied to a particular result, testing risks generating anxiety without delivering a clinical decision. The agency’s position also reflects a broader principle in environmental medicine: biomarker detection is only one part of risk interpretation, and the threshold between background exposure and meaningful harm is often difficult to define for an individual patient.
The government’s PFAS Action Plan already takes a precautionary stance, and measures have been introduced to reduce exposure to some PFAS compounds through restrictions on certain products and applications. That regulatory context matters because biomonitoring data can help assess whether such restrictions are altering exposure patterns over time. If baseline levels are established now, later measurements can show whether public health controls are having the intended effect.
International evidence review and public health implications
UKHSA is also working with international partners, including organisations across Europe, to track emerging evidence and improve understanding of potential risks. The agency’s biomonitoring work therefore sits inside a larger scientific effort rather than a single national project. PFAS exposure is a transnational issue, and cross-border collaboration is essential when environmental chemicals circulate through products, food chains, water systems, and household materials.
The independent Committee on Toxicity is carrying out its own detailed review of PFAS and health effects, adding another layer of expert scrutiny. That parallel process should help contextualise the biomonitoring findings when they arrive in 2027. For clinicians, the near-term takeaway is straightforward: current evidence does not support routine PFAS testing in asymptomatic people, and the presence of PFAS in blood does not yet map to a validated bedside intervention.
For patients worried about their health, the advice remains unchanged. Concerns should be discussed with a GP or other healthcare professional, especially when symptoms, pregnancy, occupational exposure, or environmental contamination raise a broader clinical question. The biomonitoring study may not answer every question now, but it is designed to define the exposure baseline that future health research will need.
The unresolved issue is not whether PFAS can be detected. It is how to interpret a number once it is found, and whether that number can eventually guide prevention in a way that is both evidence-based and clinically useful.